Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) ended Thursday session in green amid volatile trading. The shares closed up +0.36 points or 4.68% at $8.06 with 4.34 million shares getting traded. Post opening the session at $8.00, the shares hit an intraday low of $7.88 and an intraday high of $8.32 and the price vacillated in this range throughout the day. The company has a market cap of $1.06 billion and the numbers of outstanding shares have been calculated to be 136.68 million shares.
Achillion Pharmaceuticals, Inc. (ACHN) on Sept. 09, 2016 announced that new interim results from a phase 2a study being conducted by Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies (Janssen), were published as part of the abstracts released for the upcoming European Association for the Study of the Liver (EASL) Special Conference, September 23 – 24, 2016, in Paris, France.
This ongoing phase 2a study was designed to confirm the required dose and treatment duration for an all-oral combination regimen containing odalasvir (ODV) and AL-335 with or without simeprevir (SMV) for durations of eight or six weeks of treatment in treatment-naïve patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection.
“We are delighted by the significant progress Janssen has made in advancing the all-oral, short-duration treatment regimen of odalasvir, AL-335 and simeprevir and are impressed with the Phase 2a study results being presented. Based on these interim results, Janssen plans to advance a phase 2b program for the triple combination to further understand the potential of this 3DAA drug combination to shorten the duration of treatment for patients suffering from HCV,” commented Dr. Milind Deshpande, President and Chief Executive Officer of Achillion. “Despite recent therapeutic advances, we believe there remains a significant unmet need in addressing the global burden of hepatitis C virus in those living with the disease.”
Data included in the abstract were as of the time of submission in July 2016. Updated results, including sustained viral response 12 weeks after completion of therapy (SVR12) for all cohorts, are scheduled to be presented on Friday, September 23, 2016, in an ePoster entitled “Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection.” Interim results from cohorts 1-4, summarized in the table below, showed that the triple combination regimen was highly effective and well tolerated in non-cirrhotic patients with GT1 HCV.
Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) ended Thursday session in green amid volatile trading. The shares closed up +0.32 points or 9.76% at $3.60 with 4.34 million shares getting traded. Post opening the session at $3.66, the shares hit an intraday low of $3.52 and an intraday high of $3.83 and the price vacillated in this range throughout the day. The company has a market cap of $158.21 million and the numbers of outstanding shares have been calculated to be 45.31 million shares.
AcelRx Pharmaceuticals Inc (ACRX) on Sept. 15, 2016 announced that in an open-label Phase 3 trial (SAP303), investigational product candidate ARX-04 (sufentanil sublingual tablet 30 mcg) was well tolerated in the management of moderate-to-severe acute pain in post-operative study patients, including elderly patients and those with organ impairment. Regardless of age and organ function, approximately 2 in 3 patients had no adverse events during the study (63% of all patients, 63% of those aged ≥65 years, 62% of those with hepatic impairment, 70% of those with renal impairment). The most common adverse events were nausea and headache. On a global assessment of ARX-04 as a method of pain control, 90% of healthcare professionals and 87% of patients responded “good” or “excellent.”
“Following short-stay in-hospital surgery, post-operative patients who do not require long-term analgesia still need safe and effective short-term pain management for efficient discharge,” said Pamela Palmer, MD, PhD, co-founder and Chief Medical Officer of AcelRx Pharmaceuticals. “In the SAP303 trial, I was impressed that the majority of patients—including the majority of higher-risk patients—did not experience any adverse events.”